MCID: BRN028
MIFTS: 74

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 56 15
Adult Brain Tumor 12 56 74
Neoplasm of Brain 12 30 6
Brain Neoplasms 77 45 74
Primary Malignant Neoplasm of Brain 12 74
Malignant Neoplasm of Brain 30 74
Brain Neoplasm 12 17
Brain Tumors 56 44
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 56
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Brain Tumor, Primary 74
Primary Brain Tumor 12
Brain Tumor Primary 56
Tumor of the Brain 12
Brain Tumor, Adult 54
Bt - Brain Tumour 12
Cancer, Brain 41

Classifications:



Summaries for Brain Cancer

MedlinePlus : 44 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as adult brain tumor, is related to li-fraumeni syndrome and central neurocytoma, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 77 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 33.1 EGFR IDH1 PTEN TP53
2 central neurocytoma 32.6 ENO2 GFAP NES
3 ganglioglioma 32.6 BRAF ENO2 GFAP NES SMARCB1 TP53
4 subependymoma 32.4 ENO2 GFAP NES
5 medulloblastoma 32.3 BMI1 DMBT1 EGFR ENO2 GFAP IDH1
6 subependymal giant cell astrocytoma 32.1 ENO2 GFAP NES
7 gliomatosis cerebri 32.1 EGFR GFAP IDH1 NES PTEN TP53
8 infratentorial cancer 32.1 GFAP NES SMARCB1 TP53
9 cerebral neuroblastoma 32.1 ENO2 GFAP TP53
10 supratentorial cancer 32.0 EGFR GFAP IDH1 IDH2 MGMT NES
11 brain glioma 32.0 EGFR GFAP IDH1 MGMT NES TP53
12 atypical teratoid rhabdoid tumor 32.0 GFAP SMARCB1 TP53
13 rhabdoid cancer 31.4 ENO2 SMARCB1 TP53
14 gliosarcoma 31.1 EGFR ENO2 GFAP IDH1 MGMT NES
15 gemistocytic astrocytoma 31.0 GFAP IDH2 PTEN
16 astroblastoma 31.0 ENO2 GFAP NES
17 glioma susceptibility 1 31.0 GFAP IDH1 IDH2 TP53
18 cerebral ventricle cancer 31.0 ENO2 GFAP SMARCB1 TP53
19 protoplasmic astrocytoma 31.0 GFAP IDH2 TP53
20 oligoastrocytoma 30.9 GFAP IDH2 MGMT
21 ependymoblastoma 30.9 GFAP NES TP53
22 pilocytic astrocytoma 30.9 BRAF GFAP IDH1
23 fibrillary astrocytoma 30.9 GFAP IDH1 IDH2 MGMT TP53
24 ependymoma 30.9 EGFR ENO2 GFAP MGMT NES
25 hydrocephalus 30.9 ENO2 GFAP NES PTEN TP53
26 ewing sarcoma 30.8 ALK BMI1 EGFR ENO2 GFAP NES
27 pleomorphic xanthoastrocytoma 30.8 BRAF GFAP IDH1 MGMT SMARCB1 TP53
28 grade iii astrocytoma 30.8 DMBT1 EGFR GFAP IDH2 MGMT PTEN
29 small cell cancer of the lung 30.8 EGFR ENO2 PIK3CA PTEN TP53
30 meningioma, familial 30.8 ENO2 GFAP PTEN SMARCB1 TP53
31 glioblastoma 30.8 ALK BRAF DMBT1 EGFR IDH1 IDH2
32 glioma 30.8 BRAF DMBT1 EGFR IDH1 IDH2 MIR25
33 glioblastoma multiforme 30.7 DMBT1 EGFR GFAP IDH1 MGMT NES
34 juvenile pilocytic astrocytoma 30.6 ENO2 GFAP TP53
35 neuroma 30.6 ENO2 GFAP SMARCB1
36 adenocarcinoma 30.6 ALK BRAF EGFR PIK3CA PTEN TP53
37 small cell carcinoma 30.6 EGFR ENO2 PTEN TP53
38 esophageal cancer 30.5 BMI1 EGFR PIK3CA PTEN TP53
39 neurilemmoma 30.5 ENO2 GFAP NES SMARCB1
40 squamous cell carcinoma 30.4 BRAF EGFR PIK3CA PTEN TP53
41 squamous cell carcinoma, head and neck 30.4 BRAF EGFR IDH2 PIK3CA PTEN TP53
42 erdheim-chester disease 30.4 BRAF NRAS PIK3CA
43 giant cell glioblastoma 30.3 BRAF EGFR GFAP IDH1 MGMT PTEN
44 anaplastic oligodendroglioma 30.3 EGFR GFAP IDH2 MGMT
45 dysembryoplastic neuroepithelial tumor 30.3 GFAP IDH1 NES
46 liver angiosarcoma 30.3 ENO2 NRAS TP53
47 gastric cancer 30.2 DANCR EGFR MGMT MIR25 PIK3CA PTEN
48 oligodendroglioma 30.2 EGFR ENO2 GFAP IDH1 IDH2 MGMT
49 teratoma 30.2 ENO2 GFAP NES TP53
50 brain stem glioma 30.2 BRAF EGFR IDH1 IDH2 PIK3CA TP53

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

27 (show all 43)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.26 EGFR PIK3CA
2 Decreased viability GR00221-A-1 10.26 ALK EGFR NRAS PIK3CA SMARCB1
3 Decreased viability GR00221-A-2 10.26 PIK3CA SMARCB1
4 Decreased viability GR00221-A-3 10.26 NRAS SMARCB1
5 Decreased viability GR00221-A-4 10.26 ALK EGFR PIK3CA
6 Decreased viability GR00381-A-1 10.26 SMARCB1
7 Decreased viability GR00402-S-2 10.26 ALK EGFR NRAS PIK3CA SMARCB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.25 BMI1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.25 PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.25 EGFR PTPN11
11 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.25 TP53
12 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.25 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.25 EGFR PTPN11
14 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.25 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.25 PTPN11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.25 PTPN11
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.25 PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.25 PIK3CA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.25 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.25 TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.25 BMI1 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.25 PTPN11
23 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.25 TP53
24 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.25 BMI1 EGFR PIK3CA PTPN11 TP53
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.25 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.25 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.25 BMI1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.25 TP53
29 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.25 PTPN11
30 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.25 TP53
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.25 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.25 EGFR
33 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.25 PTPN11
34 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.25 PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.25 BMI1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.25 PTPN11
37 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.25 PTPN11
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.25 EGFR
39 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.25 BMI1
40 Decreased viability in esophageal squamous lineage GR00235-A 9.85 BRAF DMBT1 GFAP IDH1 IDH2 PIK3CA
41 Decreased cell migration GR00055-A-1 9.77 ALK BRAF EGFR EPHB2 PIK3CA
42 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.72 EGFR EPHB2 NRAS PTEN PTPN11
43 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR IDH2 NRAS PTEN PTPN11

MGI Mouse Phenotypes related to Brain Cancer:

47 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 BRAF DMBT1 EGFR ENO2 EPHB2 GFAP
2 growth/size/body region MP:0005378 10.36 ALK BRAF EGFR ENO2 EPHB2 GFAP
3 behavior/neurological MP:0005386 10.35 ALK BRAF ENO2 EPHB2 GFAP NRAS
4 homeostasis/metabolism MP:0005376 10.34 ALK BRAF DMBT1 EGFR GFAP IDH1
5 cardiovascular system MP:0005385 10.3 BRAF EGFR GFAP IDH2 NRAS PIK3CA
6 mortality/aging MP:0010768 10.3 ALK BRAF DMBT1 EGFR EPHB2 GFAP
7 digestive/alimentary MP:0005381 10.27 BRAF DMBT1 EGFR EPHB2 GFAP NRAS
8 endocrine/exocrine gland MP:0005379 10.26 ALK BRAF EGFR EPHB2 MGMT NRAS
9 immune system MP:0005387 10.25 BRAF DMBT1 EGFR GFAP IDH1 NRAS
10 embryo MP:0005380 10.22 BRAF DMBT1 EGFR NRAS PIK3CA PTEN
11 neoplasm MP:0002006 10.18 ALK BRAF DMBT1 EGFR IDH2 MGMT
12 craniofacial MP:0005382 10.13 BRAF EGFR ENO2 EPHB2 NRAS PTPN11
13 nervous system MP:0003631 10.11 ALK BRAF EGFR ENO2 EPHB2 GFAP
14 integument MP:0010771 10.1 ALK BRAF EGFR NRAS PIK3CA PTEN
15 muscle MP:0005369 10.03 BRAF EGFR GFAP PIK3CA PTEN PTPN11
16 liver/biliary system MP:0005370 10.02 BRAF EGFR NRAS PTEN PTPN11 SMARCB1
17 hearing/vestibular/ear MP:0005377 10.01 BRAF DMBT1 EGFR EPHB2 PTPN11 TP53
18 reproductive system MP:0005389 9.91 ALK BRAF EGFR EPHB2 PIK3CA PTEN
19 pigmentation MP:0001186 9.87 ALK BRAF EGFR NRAS PTEN PTPN11
20 respiratory system MP:0005388 9.81 ALK BRAF EGFR ENO2 IDH1 MGMT
21 skeleton MP:0005390 9.61 ALK BRAF EGFR IDH1 NRAS PIK3CA
22 vision/eye MP:0005391 9.36 ALK BRAF EGFR EPHB2 GFAP NRAS

Drugs & Therapeutics for Brain Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Gliadel Wafer 19 50 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 19 50 TEMOZOLOMIDE Schering-Plough August 1999
3
Alecensa 19 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 788)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
2
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
3
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
4
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
5
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
6
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
7
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
8
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 437-38-7 3345
10
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
12
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
14
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
15
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
18
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
19
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 38904 10339178 498142
20
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1401-55-4
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
22
Levetiracetam Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 102767-28-2 441341
23
Labetalol Approved Phase 4 36894-69-6 3869
24
Clevidipine Approved, Investigational Phase 4 167221-71-8
25
Hydralazine Approved Phase 4 86-54-4 3637
26
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
27
Methylphenidate Approved, Investigational Phase 4,Phase 3,Not Applicable 113-45-1 4158
28
Thrombin Approved, Investigational Phase 4
29
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
30
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
31
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
32
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
33
Pseudoephedrine Approved Phase 4 90-82-4 7028
34
Ephedrine Approved Phase 4 299-42-3 9294
35
Phenylephrine Approved Phase 4 59-42-7 6041
36
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 7487-88-9 24083
37
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
38
Propranolol Approved, Investigational Phase 4 525-66-6 4946
39
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
40
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
41
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
42
Warfarin Approved Phase 4 81-81-2 6691 54678486
43
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
44
Phylloquinone Approved, Investigational Phase 4,Phase 1 84-80-0
45
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
46
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
47
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
48
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
49
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
50
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 2116)
# Name Status NCT ID Phase Drugs
1 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Unknown status NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
4 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
5 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
6 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
7 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
8 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
9 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
10 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Completed NCT02193568 Phase 4
11 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
12 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
13 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
14 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
15 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
16 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
17 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Completed NCT02558569 Phase 4 Levobupivacaine
18 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
19 Vasopressor Effects in Anesthetized Patients Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
20 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
21 Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
22 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
23 Crossover Comparison of MultiHance and Dotarem Completed NCT02070380 Phase 4 MultiHance 0.1 mmol/kg;Dotarem;MultiHance 0.05 mmol/kg
24 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
25 A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain Completed NCT00323102 Phase 4 Multihance
26 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
27 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
28 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
29 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
30 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
31 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
32 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
33 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
34 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
35 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
36 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
37 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
38 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
39 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
40 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
41 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
42 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
43 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
44 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
45 3D Ultra Sound for Resection of Brain Tumors Unknown status NCT02150564 Phase 3
46 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
47 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
48 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
49 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
50 Local Radiotherapy Following Complete Resection of a Brain Metastasis Unknown status NCT02729558 Phase 3

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Brain 30
2 Malignant Neoplasm of Brain 30

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

42
Brain, Pituitary, Lung, Breast, T Cells, Testes, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 658)
# Title Authors Year
1
Analyses of temporal and spatial patterns of glioblastoma multiforme and other brain cancer subtypes in relation to mobile phones using synthetic counterfactuals. ( 30384227 )
2019
2
Glioblastoma's Next Top Model: Novel Culture Systems for Brain Cancer Radiotherapy Research. ( 30621226 )
2019
3
Progress in the fight against brain cancer. ( 30626956 )
2019
4
Brown Seaweed Egregia menziesii's Cytotoxic Activity against Brain Cancer Cell Lines. ( 30641974 )
2019
5
A Review on a Deep Learning Perspective in Brain Cancer Classification. ( 30669406 )
2019
6
Anticancer Effect of Cisplatin-Loaded Poly (Butylcyanoacrylate) Nanoparticles on A172 Brain Cancer Cells Line ( 30678454 )
2019
7
Fear of disease progression in adult ambulatory patients with brain cancer: prevalence and clinical correlates. ( 30684045 )
2019
8
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer. ( 30710631 )
2019
9
A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. ( 30723234 )
2019
10
The role of ACKR3 in breast, lung and brain cancer. ( 30745320 )
2019
11
Quality of Life in Brain Cancer: Clinical Validation of the Mexican-Spanish Version of the EORTC QLQ-BN20 Questionnaire. ( 30761074 )
2019
12
A meta-analysis of the association between poultry and egg consumption and the risk of brain cancer. ( 30782302 )
2019
13
Retraction Note: A homing system targets therapeutic T cells to brain cancer. ( 30787441 )
2019
14
Verteporfin-loaded polymeric microparticles for intratumoral treatment of brain cancer. ( 30803231 )
2019
15
MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer. ( 30813461 )
2019
16
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. ( 30846550 )
2019
17
Bifunctional magnetopolymersomes of iron oxide nanoparticles and carboxymethylcellulose conjugated with doxorubicin for hyperthermo-chemotherapy of brain cancer cells. ( 30869664 )
2019
18
Association between tea and coffee consumption and brain cancer risk: an updated meta-analysis. ( 30876465 )
2019
19
'It was nothing that you would think was anything': Qualitative analysis of appraisal and help seeking preceding brain cancer diagnosis. ( 30901334 )
2019
20
The effects of cucurbitacin E on GADD45β-trigger G2/M arrest and JNK-independent pathway in brain cancer cells. ( 30912292 )
2019
21
Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature? ( 29331541 )
2018
22
Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer. ( 29970101 )
2018
23
A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier. ( 29783757 )
2018
24
Does Risk of Brain Cancer Increase with Intracranial Volume? A Population-Based Case-Control Study. ( 29554311 )
2018
25
Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. ( 29603739 )
2018
26
Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. ( 29189177 )
2018
27
Brain-Resident Microglia and Blood-Borne Macrophages Orchestrate Central Nervous System Inflammation in Neurodegenerative Disorders and Brain Cancer. ( 29681904 )
2018
28
Spatio-spectral classification of hyperspectral images for brain cancer detection during surgical operations. ( 29554126 )
2018
29
Response to 'Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature?' ( 29343408 )
2018
30
Heart Variability Biofeedback as Supplementary Care for Brain Cancer: A Feasibility Study. ( 29653058 )
2018
31
Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line. ( 29597041 )
2018
32
Micro-imaging of Brain Cancer Radiation Therapy Using Phase-contrast Computed Tomography. ( 29976510 )
2018
33
Biofabrication of morphology improved cadmium sulfide nanoparticles using Shewanella oneidensis bacterial cells and ionic liquid: For toxicity against brain cancer cell lines. ( 29207279 )
2018
34
The role of income in brain tumor patients: a descriptive register-based study : No correlation between patients' income and development of brain cancer. ( 29532282 )
2018
35
Special Issue on Precision Medicine for Brain Cancer in ACS Chemical Neuroscience. ( 29338188 )
2018
36
Validation of the Chinese version of EORTC QLQ-BN20 for patients with brain cancer. ( 29461664 )
2018
37
Investigating the Ketogenic Diet As Treatment for Primary Aggressive Brain Cancer: Challenges and Lessons Learned. ( 29536011 )
2018
38
The biochemical, nanomechanical and chemometric signatures of brain cancer. ( 28688336 )
2018
39
Patients' experiences and care needs during the diagnostic phase of an integrated brain cancer pathway: A case study. ( 29603812 )
2018
40
Brain cancer genomics and epigenomics. ( 29478614 )
2018
41
Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. ( 29654697 )
2018
42
Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of golda89iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. ( 29248558 )
2018
43
Enhanced Photogeneration of Reactive Oxygen Species and Targeted Photothermal Therapy of C6 Glioma Brain Cancer Cells by Folate-Conjugated Gold-Photoactive Polymer Nanoparticles. ( 29787247 )
2018
44
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. ( 29391205 )
2018
45
Brain Cancer Imaging Phenomics Toolkit (brain-CaPTk): An Interactive Platform for Quantitative Analysis of Glioblastoma. ( 29733087 )
2018
46
The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. ( 29385679 )
2018
47
Correction: SlicerDMRI: Open Source Diffusion MRI Software for Brain Cancer Research. ( 29716952 )
2018
48
Could a plant derived protein potentiate the anticancer effects of a stem cell in brain cancer? ( 29765540 )
2018
49
Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer. ( 29259011 )
2018
50
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer. ( 29291164 )
2018